- Home
- PLBC vs MNPR Comparison
PLBC vs MNPR Comparison
Compare PLBC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- MNPR
- Stock Information
- Founded
- PLBC 1980
- MNPR 2014
- Country
- PLBC United States
- MNPR United States
- Employees
- PLBC N/A
- MNPR N/A
- Industry
- PLBC Finance Companies
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- MNPR Health Care
- Exchange
- PLBC Nasdaq
- MNPR Nasdaq
- Market Cap
- PLBC 253.9M
- MNPR 250.0M
- IPO Year
- PLBC 2005
- MNPR 2019
- Fundamental
- Price
- PLBC $44.24
- MNPR $40.25
- Analyst Decision
- PLBC Buy
- MNPR Strong Buy
- Analyst Count
- PLBC 2
- MNPR 4
- Target Price
- PLBC $57.00
- MNPR $43.00
- AVG Volume (30 Days)
- PLBC 10.8K
- MNPR 71.2K
- Earning Date
- PLBC 04-16-2025
- MNPR 03-27-2025
- Dividend Yield
- PLBC 2.71%
- MNPR N/A
- EPS Growth
- PLBC N/A
- MNPR N/A
- EPS
- PLBC 4.80
- MNPR N/A
- Revenue
- PLBC $81,275,000.00
- MNPR N/A
- Revenue This Year
- PLBC N/A
- MNPR N/A
- Revenue Next Year
- PLBC $22.44
- MNPR N/A
- P/E Ratio
- PLBC $9.22
- MNPR N/A
- Revenue Growth
- PLBC 4.55
- MNPR N/A
- 52 Week Low
- PLBC $32.50
- MNPR $1.72
- 52 Week High
- PLBC $51.33
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- PLBC 40.76
- MNPR 49.34
- Support Level
- PLBC $44.43
- MNPR $38.80
- Resistance Level
- PLBC $46.11
- MNPR $45.60
- Average True Range (ATR)
- PLBC 1.09
- MNPR 5.19
- MACD
- PLBC -0.15
- MNPR -1.50
- Stochastic Oscillator
- PLBC 0.00
- MNPR 9.37
About PLBC Plumas Bancorp
Plumas Bancorp is a bank holding company that provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.